Study to Evaluate the Efficacy and Safety of Exenatide Once-Weekly Injection Compared to Once-Daily Insulin in Type 2 Diabetes Mellitus

NCT00935532 on ClinicalTrials.gov · last registry update 2015-06-15

Finished September 2010, after enrolling 427 people. Primary outcome, as filed: Change in HbA1c From Baseline to Endpoint (Week 26). exenatide is already approved in the US for type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.

Status: COMPLETED
Phase: P3
Drug: exenatide
Bydureon, Byetta
Sponsor: AstraZeneca
Sponsor type: Industry
Enrollment: 427
Started: 2009-07
Primary completion: 2010-09 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Change in HbA1c From Baseline to Endpoint (Week 26)

Conditions studied

Type 2 Diabetes Mellitus

Every field above is taken directly from the registry record. See all detected changes across the class, or the exenatide page for this molecule’s full trial and approval history.